Sunvozertinib and Ketoconazole Topical: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Ketoconazole Topical
Sunvozertinib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased sunvozertinib exposure and an increased risk sunvozertinib-related adverse reactions
Interaction Deep Dive
Avoid concomitant use of sunvozertinib with strong CYP3A inhibitors as it may increase sunvozertinib exposure, which may increase the risk of sunvozertinib adverse reactions. In drug interaction studies, sunvozertinib AUC increased by 1.5-fold and Cmax by 1.3-fold following concomitant administration of itraconazole (strong CYP3A inhibitor) 200 mg once daily. If concomitant use cannot be avoided, reduce the sunvozertinib dose from 200 mg to 150 mg and monitor for increased sunvozertinib adverse reactions. After discontinuing a strong CYP3A inhibitor, resume the sunvozertinib dose (after 3 to 5 half-lives of the strong CYP3A inhibitor) that was taken prior to initiating the strong CYP3A inhibitor1.
Why it happens (mechanism)
Inhibition of CYP3A-mediated metabolism of sunvozertinib
Literature reports
1 report — tap to read
a) In drug interaction studies, sunvozertinib AUC increased by 1.5-fold and Cmax by 1.3-fold following concomitant administration of itraconazole (strong CYP3A inhibitor) 200 mg once daily 1.
Common questions
Can I take Sunvozertinib and Ketoconazole Topical together?
Increased sunvozertinib exposure and an increased risk sunvozertinib-related adverse reactions Always confirm with your pharmacist or prescriber before making any change.
How serious is the Sunvozertinib and Ketoconazole Topical interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Sunvozertinib or Ketoconazole Topical need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: ZEGFROVY(TM) oral tablets, sunvozertinib oral tablets. Dizal (Jiangsu) Pharmaceutical Co. Ltd (per FDA), Shanghai, China, 2025.
Keep reading about Ketoconazole Topical
Keep reading about Sunvozertinib
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist